Aspirin therapy is still underutilized among patients with type 2 diabetes
Autor(a) principal: | |
---|---|
Data de Publicação: | 2006 |
Outros Autores: | , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Arquivos Brasileiros de Endocrinologia & Metabologia (Online) |
Texto Completo: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302006000600006 |
Resumo: | The daily use of aspirin in patients with type 2 diabetes mellitus (DM2) reduces significantly cardiovascular events (CVE). In the absence of contraindications, American Diabetes Association (ADA) recommends the use of aspirin to all DM2 patients older than 40 years of age. To evaluate aspirin use among 636 out patients with DM2 who participate in a regional multicenter study in Southern Brazil, a standard questionnaire was used. Patients also underwent a physical examination and laboratorial tests. All patients were older than 40 years (mean 58 ± 11 years old; 42% male) and by ADA guidelines most of them should be using aspirin. However, only 177 (27.5%) were on this medication. The use of aspirin was higher when any CVE were present. However, the percentage of users was still below the expected, not even reaching 50%. In conclusion, even though the use of aspirin is greater in patients with CVE, and its benefits are well documented, it is still underutilized. Strategies to enhance the use of aspirin should be developed to reduce the morbidity and mortality from cardiovascular diseases in patients with DM2. |
id |
SBEM-2_a92f901e4db4b45df42853885aede984 |
---|---|
oai_identifier_str |
oai:scielo:S0004-27302006000600006 |
network_acronym_str |
SBEM-2 |
network_name_str |
Arquivos Brasileiros de Endocrinologia & Metabologia (Online) |
repository_id_str |
|
spelling |
Aspirin therapy is still underutilized among patients with type 2 diabetesAspirinType 2 diabetes mellitusCardiovascular diseaseADA guidelinesThe daily use of aspirin in patients with type 2 diabetes mellitus (DM2) reduces significantly cardiovascular events (CVE). In the absence of contraindications, American Diabetes Association (ADA) recommends the use of aspirin to all DM2 patients older than 40 years of age. To evaluate aspirin use among 636 out patients with DM2 who participate in a regional multicenter study in Southern Brazil, a standard questionnaire was used. Patients also underwent a physical examination and laboratorial tests. All patients were older than 40 years (mean 58 ± 11 years old; 42% male) and by ADA guidelines most of them should be using aspirin. However, only 177 (27.5%) were on this medication. The use of aspirin was higher when any CVE were present. However, the percentage of users was still below the expected, not even reaching 50%. In conclusion, even though the use of aspirin is greater in patients with CVE, and its benefits are well documented, it is still underutilized. Strategies to enhance the use of aspirin should be developed to reduce the morbidity and mortality from cardiovascular diseases in patients with DM2.Sociedade Brasileira de Endocrinologia e Metabologia2006-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302006000600006Arquivos Brasileiros de Endocrinologia & Metabologia v.50 n.6 2006reponame:Arquivos Brasileiros de Endocrinologia & Metabologia (Online)instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)instacron:SBEM10.1590/S0004-27302006000600006info:eu-repo/semantics/openAccessLeitão,Cristiane B.Krahe,Ana L.Nabinger,Gustavo B.Picon,Paula X.Pecis,MiriamZaslavsky,Lérida M.Gross,Jorge L.Canani,Luis H.eng2007-01-08T00:00:00Zoai:scielo:S0004-27302006000600006Revistahttps://www.aem-sbem.com/ONGhttps://old.scielo.br/oai/scielo-oai.php||abem-editoria@endocrino.org.br1677-94870004-2730opendoar:2007-01-08T00:00Arquivos Brasileiros de Endocrinologia & Metabologia (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)false |
dc.title.none.fl_str_mv |
Aspirin therapy is still underutilized among patients with type 2 diabetes |
title |
Aspirin therapy is still underutilized among patients with type 2 diabetes |
spellingShingle |
Aspirin therapy is still underutilized among patients with type 2 diabetes Leitão,Cristiane B. Aspirin Type 2 diabetes mellitus Cardiovascular disease ADA guidelines |
title_short |
Aspirin therapy is still underutilized among patients with type 2 diabetes |
title_full |
Aspirin therapy is still underutilized among patients with type 2 diabetes |
title_fullStr |
Aspirin therapy is still underutilized among patients with type 2 diabetes |
title_full_unstemmed |
Aspirin therapy is still underutilized among patients with type 2 diabetes |
title_sort |
Aspirin therapy is still underutilized among patients with type 2 diabetes |
author |
Leitão,Cristiane B. |
author_facet |
Leitão,Cristiane B. Krahe,Ana L. Nabinger,Gustavo B. Picon,Paula X. Pecis,Miriam Zaslavsky,Lérida M. Gross,Jorge L. Canani,Luis H. |
author_role |
author |
author2 |
Krahe,Ana L. Nabinger,Gustavo B. Picon,Paula X. Pecis,Miriam Zaslavsky,Lérida M. Gross,Jorge L. Canani,Luis H. |
author2_role |
author author author author author author author |
dc.contributor.author.fl_str_mv |
Leitão,Cristiane B. Krahe,Ana L. Nabinger,Gustavo B. Picon,Paula X. Pecis,Miriam Zaslavsky,Lérida M. Gross,Jorge L. Canani,Luis H. |
dc.subject.por.fl_str_mv |
Aspirin Type 2 diabetes mellitus Cardiovascular disease ADA guidelines |
topic |
Aspirin Type 2 diabetes mellitus Cardiovascular disease ADA guidelines |
description |
The daily use of aspirin in patients with type 2 diabetes mellitus (DM2) reduces significantly cardiovascular events (CVE). In the absence of contraindications, American Diabetes Association (ADA) recommends the use of aspirin to all DM2 patients older than 40 years of age. To evaluate aspirin use among 636 out patients with DM2 who participate in a regional multicenter study in Southern Brazil, a standard questionnaire was used. Patients also underwent a physical examination and laboratorial tests. All patients were older than 40 years (mean 58 ± 11 years old; 42% male) and by ADA guidelines most of them should be using aspirin. However, only 177 (27.5%) were on this medication. The use of aspirin was higher when any CVE were present. However, the percentage of users was still below the expected, not even reaching 50%. In conclusion, even though the use of aspirin is greater in patients with CVE, and its benefits are well documented, it is still underutilized. Strategies to enhance the use of aspirin should be developed to reduce the morbidity and mortality from cardiovascular diseases in patients with DM2. |
publishDate |
2006 |
dc.date.none.fl_str_mv |
2006-12-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302006000600006 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302006000600006 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1590/S0004-27302006000600006 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Sociedade Brasileira de Endocrinologia e Metabologia |
publisher.none.fl_str_mv |
Sociedade Brasileira de Endocrinologia e Metabologia |
dc.source.none.fl_str_mv |
Arquivos Brasileiros de Endocrinologia & Metabologia v.50 n.6 2006 reponame:Arquivos Brasileiros de Endocrinologia & Metabologia (Online) instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) instacron:SBEM |
instname_str |
Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) |
instacron_str |
SBEM |
institution |
SBEM |
reponame_str |
Arquivos Brasileiros de Endocrinologia & Metabologia (Online) |
collection |
Arquivos Brasileiros de Endocrinologia & Metabologia (Online) |
repository.name.fl_str_mv |
Arquivos Brasileiros de Endocrinologia & Metabologia (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) |
repository.mail.fl_str_mv |
||abem-editoria@endocrino.org.br |
_version_ |
1754734808484806656 |